# EDGAR Filing Document

**Accession Number:** 0001808865
**File Stem:** 0001140361-25-034293
**Filing Date:** 2025-9
**Character Count:** 2999
**Document Hash:** d1170f192f20373ef9faa3e2bf530cb1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-25-034293.hdr.sgml**: 20250908

**ACCESSION NUMBER**: 0001140361-25-034293

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250908

**DATE AS OF CHANGE**: 20250908

**EFFECTIVENESS DATE**: 20250908

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** iTeos Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001808865
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39401
- **FILM NUMBER:** 251300191

**BUSINESS ADDRESS:**
- **STREET 1:** 321 ARSENAL STREET
- **STREET 2:** BLDG 312, FLOOR 3, SUITE 301
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
- **BUSINESS PHONE:** 857-204-4583

**MAIL ADDRESS:**
- **STREET 1:** 321 ARSENAL STREET
- **STREET 2:** BLDG 312, FLOOR 3, SUITE 301
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 15

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.**

---

| |
|:---|
| **001-39401** |
| Commission File Number |

---

---

| |
|:---|
| **ITEOS THERAPEUTICS, INC.** |
| (Exact name of registrant as speciﬁed in its charter) |

---

---

| |
|:---|
| **321 Arsenal St** |
| **Watertown, MA 02472** |
| (339) 217-0162 |
| (Address, including zip code, and telephone number, including area code, of registrant's principal executive ofﬁces) |

---

---

| |
|:---|
| **Common Stock, $0.001 par value per share** |
| (Title of each class of securities covered by this Form) |

---

---

| |
|:---|
| **None** |
| (Titles of all other classes of securities for which a duty to ﬁle reports under section 13(a) or 15(d) remains) |

---

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to ﬁle reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | ☒ |
| Rule 12g-4(a)(2) | ☐ |
| Rule 12h-3(b)(1)(i) | ☒ |
| Rule 12h-3(b)(1)(ii) | ☐ |
| Rule 15d-6 | ☐ |
| Rule 15d-22(b) | ☐ |

---

Approximate number of holders of record as of the certiﬁcation or notice date: <u> One </u>

Pursuant to the requirements of the Securities Exchange Act of 1934, iTeos Therapeutics, Inc. has caused this certiﬁcation/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
| Date: September 8, 2025 | **ITEOS THERAPEUTICS, INC.** | **ITEOS THERAPEUTICS, INC.** |
|  | By: | /s/ Michael Hearne |
|  |  | Name: Michael Hearne |
|  |  | Title: *Chief Financial Officer* |

---

------